SANA - Rasio utang marang kapitalisasi buku Sana Biotechnology

Logo korporat perusahaan Sana Biotechnology, Inc. (SANA)

The operational foundation of Sana Biotechnology (SANA) remains stable due to the humanitarian status of biotechnologies and the protection of rights in the US. The share price history on the GURU.Markets platform, where the indicator stands at 0.46, reflects complex certification processes and prolonged R&D expenditures. The business relies on developing methods to mask cells from the immune system, which creates a significant technological moat and attracts strategic partners.

SANA Sana Biotechnology: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 28.10.2026

Ringkesan rincian data analitis Sana Biotechnology Inc (SANA)

- rega lan prakiraan konsensus rega:
Rega saham Sana Biotechnology|SANA - Target konsensus
- data kapitalisasi pasar:
Nilai pasar Sana Corp|SANA - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Sana Biotechnology|SANA - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku sana.com|SANA - Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Sana Biotechnology|SANA - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Sana Bio|SANA - Utang kumulatif perusahaan|Utang marang nilai buku Sana Corp
Analisis kabeh metrik perusahaan:SANA, Sana Biotechnology
Produk dadi Sana Corp

Developing innovative cell therapy methods requires colossal expenditures; therefore, correlating debt levels with balance sheet capital allows for an assessment of the funding stability for R&D projects at Sana Biotechnology (SANA). This ratio measures the proportion of borrowed funds within the equity structure, helping investors determine the level of financial leverage and the risk of liquidity loss during the implementation of a long-term expansion strategy in the gene medicine market.

Pesaing Sana Biotechnology

Legend Biotech - Utang-utang marang kapitalisasi buku|autolus.com - Utang marang nilai buku|ALLO (Allogene) - Rasio utang marang kapitalisasi buku|RNAC: Utang-utang marang nilai buku|cellectis.com (CLLS) - Rasio utang marang kapitalisasi buku|CRBU (Caribou Biosciences, Inc) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku TIL (Instil Bio, Inc.)|Utang-utang marang nilai buku Genenta|IPSC: Utang-utang marang kapitalisasi buku|Utang marang aset resik jaspertherapeutics.com JSPR|SNTI: Utang marang nilai buku|ADAP - Utang-utang marang nilai buku|Utang marang nilai buku CERo Therapeutics Holdings Inc. (CERO)|TCRT - Rasio utang marang aset resik|ACHL (achillestx.com) - Utang-utang marang kapitalisasi buku|CARGO Therapeutics Inc. (CRGX) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku PSTX (Poseida)|Utang-utang marang nilai buku TSVT|Rasio utang marang kapitalisasi buku Gracell Biotechnologies (GRCL)